Portal de Periódicos da CAPES

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin

2003; Elsevier BV; Volume: 3; Issue: 4 Linguagem: Inglês

10.1016/s1471-4892(03)00083-3

1471-4973

Nitin K. Damle,

Cancer therapeutics and mechanisms

Targeted delivery of cytotoxic agents to tumours is believed to improve both their anti-tumour efficacy and their safety. Antibodies specific for tumour-associated antigens have been used to deliver cytotoxic agents to tumour cells. Calicheamicin is a potent cytotoxic agent that causes double-strand DNA breaks, resulting in cell death. When conjugated to monoclonal antibodies specific for tumour-associated antigens, calicheamicin exerts strong antigen-specific anti-tumour effects against human tumour xenografts in preclinical models. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Mylotarg), is a clinically validated therapeutic strategy for the treatment of human cancer.